IMI launches latest €95m call
The Innovative Medicines Initiative (IMI) has announced details of its 5th call for proposals under the IMI 2 programme.
The call has a total budget of €95m and focuses on six topics. The first four areas focus on different aspects of Alzheimer’s disease, whilst the further two focus on diabetic kidney disease and addresses patient input on assessments of the benefits and risks of medicines respectively.
Commenting Irene Norstedt, IMI acting executive director, said: “With the launch of this call for proposals, IMI once again affirms its commitment to tackling some of the biggest public health challenges facing Europe today – Alzheimer’s disease and diabetes. At the same time, the fact that we have two topics dedicated to patient engagement underlines IMI’s role as a platform for multistakeholder collaboration.”
Half of the call’s budget (€47.5m) is drawn from the European Commission through Horizon 2020, whilst the remaining funding comes from European Federation of Pharmaceutical Industries and Associations companies involved in the projects, as well as other associated partners. These groups do not receive any funding from IMI, but contribute ‘in kind’ with their researchers’ time, access to resources and equipment, etc.
The deadline for submitting short proposals is 13 October 2015.
